Tawfik Khoury1,2, Muhammad Massarwa3,4, Wadi Hazou3,5, Saleh Daher3,4, David Hakimian3,4, Ariel A Benson3,6, Toni Ashqar3, Mahmud Mahamid7, Shaul Yaari3. 1. Institute of Gastroenterology and Liver Diseases, Department of Internal Medicine, Hebrew University-Hadassah Medical Center, P.O.B. 12000, IL-91120, Jerusalem, Israel. tawfikkhoury1@hotmail.com. 2. The Liver Unit, Institute of Gastroenterology and Liver Diseases, Division of Internal Medicine, Hebrew University-Hadassah Medical Center, P.O.B. 12000, IL-91120, Jerusalem, Israel. tawfikkhoury1@hotmail.com. 3. Institute of Gastroenterology and Liver Diseases, Department of Internal Medicine, Hebrew University-Hadassah Medical Center, P.O.B. 12000, IL-91120, Jerusalem, Israel. 4. The Liver Unit, Institute of Gastroenterology and Liver Diseases, Division of Internal Medicine, Hebrew University-Hadassah Medical Center, P.O.B. 12000, IL-91120, Jerusalem, Israel. 5. The Liver Unit, Institute of Gastroenterology and Liver Diseases, Hebrew University-Hadassah Medical Center, P.O.B. 12000, IL-91120, Jerusalem, Israel. 6. Institute of Gastroenterology and Liver Diseases, Hebrew University-Hadassah Medical Center, P.O.B. 12000, IL-91120, Jerusalem, Israel. 7. Gastroenterology and Endoscopy United, The Nazareth Hospital, EMMS, Nazareth, Israel.
Abstract
PURPOSE: Portal vein thrombosis (PVT) is a common condition in cirrhotic patients and mostly attributed to portal hypertension. The objective of our study was to examine the association of PVT with hepatocellular carcinoma (HCC) in cirrhotic patients. METHODS: A retrospective study was performed to identify cirrhotic patients with thrombosis of the portal system. Clinical and laboratory characteristics were collected and analyzed. RESULTS: Thirty-nine patients were identified. Twenty-four out of 39 patients with PVT did not develop HCC (group A) after follow-up time of 38.5 months from the diagnosis of PVT. Eight patients (20.5%) were diagnosed with HCC within two weeks following diagnosis of PVT (group B). Seven patients (17.9%) were diagnosed with tumor thrombus (group C) at time of PVT diagnosis. The average age was 53.5, 66.5, and 69 years for groups A, B, and C respectively. Most patients (75 and 87.5% for groups B and C respectively) diagnosed with PVT and HCC were males. The most common cause of cirrhosis in groups B and C was chronic hepatitis B virus infection (HBV) in 62.5% and 50% respectively. The most common clinical presentation of PVT in group A was abdominal pain in 55.5% compared to new/worsening ascites in 43% and 37.5% for groups B and C respectively. The platelet count in groups B and C was higher as compared to that in group A (126 and 125 vs. 107 thousand, P = NS). CONCLUSION: In 38.4% of cases, new diagnosis of PVT was associated with concomitant diagnosis of HCC. Identifiable risk factors were chronic HBV infection and higher platelet count.
PURPOSE: Portal vein thrombosis (PVT) is a common condition in cirrhotic patients and mostly attributed to portal hypertension. The objective of our study was to examine the association of PVT with hepatocellular carcinoma (HCC) in cirrhotic patients. METHODS: A retrospective study was performed to identify cirrhotic patients with thrombosis of the portal system. Clinical and laboratory characteristics were collected and analyzed. RESULTS: Thirty-nine patients were identified. Twenty-four out of 39 patients with PVT did not develop HCC (group A) after follow-up time of 38.5 months from the diagnosis of PVT. Eight patients (20.5%) were diagnosed with HCC within two weeks following diagnosis of PVT (group B). Seven patients (17.9%) were diagnosed with tumor thrombus (group C) at time of PVT diagnosis. The average age was 53.5, 66.5, and 69 years for groups A, B, and C respectively. Most patients (75 and 87.5% for groups B and C respectively) diagnosed with PVT and HCC were males. The most common cause of cirrhosis in groups B and C was chronic hepatitis B virus infection (HBV) in 62.5% and 50% respectively. The most common clinical presentation of PVT in group A was abdominal pain in 55.5% compared to new/worsening ascites in 43% and 37.5% for groups B and C respectively. The platelet count in groups B and C was higher as compared to that in group A (126 and 125 vs. 107 thousand, P = NS). CONCLUSION: In 38.4% of cases, new diagnosis of PVT was associated with concomitant diagnosis of HCC. Identifiable risk factors were chronic HBV infection and higher platelet count.
Authors: B V John; R Konjeti; A Aggarwal; R Lopez; A Atreja; C Miller; N N Zein; W D Carey Journal: Ann Hepatol Date: 2013 Nov-Dec Impact factor: 2.400
Authors: C Francoz; J Belghiti; V Vilgrain; D Sommacale; V Paradis; B Condat; M H Denninger; A Sauvanet; D Valla; F Durand Journal: Gut Date: 2005-05 Impact factor: 23.059
Authors: A Mangia; M Margaglione; I Cascavilla; R Gentile; G Cappucci; D Facciorusso; E Grandone; G Di Minno; M Rizzetto; A Andriulli Journal: Am J Gastroenterol Date: 1999-10 Impact factor: 10.864
Authors: Laura Lladó; Juan Fabregat; José Castellote; Emilio Ramos; Jaume Torras; Rosa Jorba; Francisco Garcia-Borobia; Juli Busquets; Juan Figueras; Antoni Rafecas Journal: Clin Transplant Date: 2007 Nov-Dec Impact factor: 2.863
Authors: Martine J Hollestelle; Hendrika G M Geertzen; Irene H Straatsburg; Thomas M van Gulik; Jan A van Mourik Journal: Thromb Haemost Date: 2004-02 Impact factor: 5.249
Authors: Maria Assunta Zocco; Enrico Di Stasio; Raimondo De Cristofaro; Marialuisa Novi; Maria Elena Ainora; Francesca Ponziani; Laura Riccardi; Stefano Lancellotti; Angelo Santoliquido; Roberto Flore; Maurizio Pompili; Gian Lodovico Rapaccini; Paolo Tondi; Giovanni Battista Gasbarrini; Raffaele Landolfi; Antonio Gasbarrini Journal: J Hepatol Date: 2009-04-23 Impact factor: 25.083